Yabao Pharmaceutical Group announced that its wholly-owned subsidiary Yabao Pharmaceutical Sichuan Co., Ltd. has recently received the registration certificate for the oral solution of ambroxol issued by the National Medical Products Administration. This pharmaceutical is mainly used to alleviate symptoms of respiratory diseases and is suitable for treating cough, thick phlegm, difficulty in expectoration, and wheezing caused by acute and chronic respiratory diseases. In 2023, the sales amount of the oral solution of ambroxol in domestic public hospitals was approximately 0.384 billion yuan, and the sales amount in physical pharmacies was approximately 0.312 billion yuan. The company has currently invested 4.2994 million yuan in research and development expenses for this project.